Allogene Therapeutics, Inc. - ALLO STOCK NEWS

Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced the publication of a case study in Molecular Therapy focusing on a single patient who experienced a chromosomal rearrangement after receiving the gene-edited CAR T treatment, ALLO-501A. The investigation determined that the chromosomal inversion was unrelated to gene editing or manufacturing processes, and held no clinical significance. Following a clinical hold by the FDA due to initial concerns, the hold was lifted three months later. This case reinforces the understanding of genomic variability in CAR T treatments and highlights the importance of cell-intrinsic biology in therapeutic applications.

Allogene Therapeutics (Nasdaq: ALLO) announced the initiation of the industry's first potentially pivotal Phase 2 allogeneic CAR T trial, ALPHA2, for relapsed/refractory large B cell lymphoma, enrolling 100 patients. Data shows comparable six-month progression-free survival to autologous therapies. The company reported a net loss of $94.8 million for Q4 2022, totaling $332.6 million for the year. Allogene ended 2022 with $576 million in cash and expects a $250 million decrease in cash reserves for 2023, with a runway into 2025. Financial guidance includes $350 million in GAAP operating expenses.

Allogene Therapeutics (Nasdaq: ALLO) will report its fourth quarter and year-end 2022 financial results on February 28, 2023, following a conference call at 2:00 PM PT/5:00 PM ET. Investors can listen to the live audio webcast on the company's website, which will be available for replay for 30 days. Allogene is focused on developing allogeneic CAR T products for cancer and aims to create readily available cell therapies. The company highlights ongoing efforts in the cell therapy space and emphasizes its management team's expertise.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) recently presented preclinical data on its innovative Dagger technology at the Keystone Symposia in Banff, Canada. This new platform aims to prevent immune rejection of AlloCAR T cells, allowing for enhanced persistence and efficacy against cancer. The Dagger technology is integral to ALLO-316, targeting CD70 in renal cell carcinoma within the ongoing Phase 1 TRAVERSE study. Preclinical findings indicate improved AlloCAR T cell survival and effectiveness in targeting tumors. The firm plans to leverage this technology across various hematologic malignancies and solid tumors, aiming to advance patient outcomes.

Allogene Therapeutics has announced promising preclinical results for its AlloCAR T™ candidate, ALLO-213, targeting DLL3 in small cell lung cancer (SCLC). Published in Clinical Cancer Research, the study highlights that ALLO-213 effectively controls tumor growth while exhibiting no off-tumor toxicity. SCLC is a highly aggressive cancer with limited therapies, affecting about 30,000 patients annually in the U.S., and has a 5-year survival rate of only 7%. This development positions Allogene favorably in the expanding field of allogeneic CAR T therapies, particularly for challenging solid tumors.

ALLO-715, an allogeneic anti-BCMA CAR T candidate, has shown promising results in the Phase 1 UNIVERSAL trial for relapsed/refractory multiple myeloma, as reported in Nature Medicine. This trial is the first to document significant therapeutic responses from a single dose of an allogeneic CAR T therapy. The initial data from 48 heavily pretreated patients show response rates comparable to established autologous CAR T therapies. The safety profile is manageable, with 92% of patients treated and all products meeting specifications, suggesting a potential shift toward off-the-shelf cell therapies, improving accessibility for patients. Next steps include advancing the trial to Phase 2.

Allogene Therapeutics (Nasdaq: ALLO) announced its participation in two investor conferences in January and February 2023. The company will attend the B. Riley Securities’ 3rd Annual Oncology Conference on January 18, 2023, at 7:00 AM PT and the 5th Annual Guggenheim Oncology Days on February 9, 2023, at 6:35 AM PT. Webcasts from these events will be available on the company's website, allowing for replay for 30 days. Allogene is developing allogeneic CAR T cell therapies, aiming to provide more accessible cancer treatments. For updates, visit www.allogene.com.

Allogene Therapeutics, a clinical-stage biotechnology company focused on allogeneic CAR T therapies, announced that Dr. David Chang will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:45 p.m. PT, in San Francisco. The presentation will be accessible via a live audio webcast on the company’s website, followed by a replay available for 30 days. Allogene is committed to advancing cell therapy to make it more accessible and reliable for patients.

Allogene Therapeutics announced the appointment of Zachary J. Roberts, M.D., Ph.D., as Executive Vice President of Research and Development. This key leadership change follows the resignation of Rafael Amado, M.D. Dr. Roberts brings extensive experience from Instil Bio and Kite Pharma, where he played a crucial role in developing CAR T therapies. Allogene aims to expedite its pipeline, highlighted by recent positive clinical data for its AlloCAR T candidates like ALLO-501A for large B cell lymphoma. The company is set to initiate pivotal trials in 2023, including the EXPAND and ALPHA2 trials.